PMID- 33603005
OWN - NLM
STAT- MEDLINE
DCOM- 20211208
LR  - 20211214
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Feb 18
TI  - Longitudinal analysis of safety and medication adherence of patients in the 
      Fingolimod patient support program: a real-world observational study.
PG  - 4107
LID - 10.1038/s41598-021-83220-1 [doi]
LID - 4107
AB  - The Fingolimod Patient Support Program (F-PSP) is an interprofessional specialty 
      pharmacy service designed to ensure responsible use of fingolimod by promoting 
      patient safety and medication adherence. This study aims to evaluate the safety 
      and medication adherence of patients who joined the F-PSP between 2013 and 2016. 
      Sociodemographic and medical characteristics, patient safety data 
      (patient-reported symptoms, discontinuations due to adverse events (AEs), 
      repeated first-dose monitoring), and medication adherence (implementation, 
      persistence, reasons for discontinuation, influence of covariates, barriers and 
      facilitators) were described. Sixty-seven patients joined the F-PSP. Patients 
      reported a high frequency of symptoms. Due to AEs, 7 patients discontinued 
      fingolimod, 3 took therapeutic breaks, and 1 reduced the regimen temporarily. 
      Three patients repeated the first-dose monitoring. Patients had a high medication 
      adherence over the 18-month analysis period: implementation decreased from 98.8 
      to 93.7%, and fingolimod persistence was 83.2% at 18 months. The patients' level 
      of education, professional situation, and living with child(ren) influenced 
      implementation. Patients reported more facilitators of medication adherence than 
      barriers. The F-PSP seems valuable for supporting individual patients (ensuring 
      responsible use of fingolimod and inviting patients for shared-decision making) 
      and public health (indirectly gathering real-world evidence).
FAU - Bourdin, Aline
AU  - Bourdin A
AUID- ORCID: 0000-0002-1331-4557
AD  - Community Pharmacy, Center for Primary Care and Public Health (Unisante), 
      University of Lausanne, Lausanne, Switzerland. aline.bourdin@unisante.ch.
AD  - School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland. 
      aline.bourdin@unisante.ch.
AD  - Institute of Pharmaceutical Sciences of Western Switzerland, University of 
      Geneva, University of Lausanne, Geneva, Switzerland. aline.bourdin@unisante.ch.
FAU - Schneider, Marie Paule
AU  - Schneider MP
AUID- ORCID: 0000-0002-7557-9278
AD  - School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
AD  - Institute of Pharmaceutical Sciences of Western Switzerland, University of 
      Geneva, University of Lausanne, Geneva, Switzerland.
FAU - Locatelli, Isabella
AU  - Locatelli I
AD  - DFRI, Center for Primary Care and Public Health (Unisante), University of 
      Lausanne, Lausanne, Switzerland.
FAU - Schluep, Myriam
AU  - Schluep M
AD  - Division of Neurology, Department of Clinical Neurosciences, Centre Hospitalier 
      Universitaire Vaudois, Lausanne, Switzerland.
FAU - Bugnon, Olivier
AU  - Bugnon O
AUID- ORCID: 0000-0003-2249-1245
AD  - Community Pharmacy, Center for Primary Care and Public Health (Unisante), 
      University of Lausanne, Lausanne, Switzerland.
AD  - School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
AD  - Institute of Pharmaceutical Sciences of Western Switzerland, University of 
      Geneva, University of Lausanne, Geneva, Switzerland.
FAU - Berger, Jerome
AU  - Berger J
AUID- ORCID: 0000-0003-1177-5453
AD  - Community Pharmacy, Center for Primary Care and Public Health (Unisante), 
      University of Lausanne, Lausanne, Switzerland.
AD  - School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
AD  - Institute of Pharmaceutical Sciences of Western Switzerland, University of 
      Geneva, University of Lausanne, Geneva, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20210218
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Immunosuppressive Agents)
RN  - G926EC510T (Fingolimod Hydrochloride)
SB  - IM
MH  - Adult
MH  - Female
MH  - Fingolimod Hydrochloride/adverse effects/*therapeutic use
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects/*therapeutic use
MH  - Longitudinal Studies
MH  - Male
MH  - Medication Adherence/*statistics & numerical data
MH  - Multiple Sclerosis, Relapsing-Remitting/*drug therapy
MH  - Patient Safety
MH  - Surveys and Questionnaires
PMC - PMC7892872
COIS- The authors declare the following potential conflicts of interest with respect to 
      the research, authorship, and/or publication of this article: O.B. was a member 
      of the advisory board of SISPha SA. MS has served as a consultant for 
      Merck-Serono and has received honoraria, payment for development of educational 
      presentations, and travel support from Merck-Serono, Biogen Idec, Novartis, 
      Sanofi-Aventis, Bayer Schering, Roche, and Genzyme. All other authors declare no 
      competing interests.
EDAT- 2021/02/20 06:00
MHDA- 2021/12/15 06:00
PMCR- 2021/02/18
CRDT- 2021/02/19 05:59
PHST- 2020/08/19 00:00 [received]
PHST- 2021/01/28 00:00 [accepted]
PHST- 2021/02/19 05:59 [entrez]
PHST- 2021/02/20 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/02/18 00:00 [pmc-release]
AID - 10.1038/s41598-021-83220-1 [pii]
AID - 83220 [pii]
AID - 10.1038/s41598-021-83220-1 [doi]
PST - epublish
SO  - Sci Rep. 2021 Feb 18;11(1):4107. doi: 10.1038/s41598-021-83220-1.